Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $13.17

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $13.17.

FULC has been the topic of several analyst reports. Piper Sandler upped their target price on Fulcrum Therapeutics from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. HC Wainwright upped their price objective on Fulcrum Therapeutics from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Royal Bank of Canada started coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They set an “outperform” rating and a $14.00 target price on the stock. Finally, The Goldman Sachs Group increased their price target on shares of Fulcrum Therapeutics from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th.

Fulcrum Therapeutics Stock Up 0.7 %

Shares of FULC opened at $7.59 on Friday. The company has a 50 day moving average of $9.00 and a 200-day moving average of $7.17. The stock has a market capitalization of $471.72 million, a P/E ratio of -4.80 and a beta of 2.35. Fulcrum Therapeutics has a twelve month low of $2.65 and a twelve month high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.04. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 36.65%. The business had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.65 million. On average, sell-side analysts anticipate that Fulcrum Therapeutics will post -1.76 earnings per share for the current fiscal year.

Insider Activity at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, VP Greg Tourangeau sold 4,884 shares of Fulcrum Therapeutics stock in a transaction on Friday, March 8th. The shares were sold at an average price of $11.72, for a total transaction of $57,240.48. Following the completion of the transaction, the vice president now directly owns 11,807 shares of the company’s stock, valued at $138,378.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds have recently bought and sold shares of FULC. Hudson Bay Capital Management LP bought a new stake in shares of Fulcrum Therapeutics in the third quarter valued at about $872,000. ClariVest Asset Management LLC bought a new stake in Fulcrum Therapeutics in the 3rd quarter valued at about $464,000. FMR LLC grew its position in shares of Fulcrum Therapeutics by 7.6% during the 3rd quarter. FMR LLC now owns 5,975,416 shares of the company’s stock worth $26,531,000 after purchasing an additional 421,676 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Fulcrum Therapeutics during the third quarter worth approximately $268,000. Finally, Jump Financial LLC acquired a new stake in shares of Fulcrum Therapeutics in the third quarter valued at approximately $408,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.